provider
Search result for "Solr search content"
Search Result for "hematology"
Clinical Trial
A Multicenter Phase 1 Study to Determine the Maximum Tolerated Dose/ Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases (CTMS# 21-0138)
This is an open-label, multicenter, Phase 1 dose-escalation study to establish the safety and tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) and to identify a maximum tolerated dose (MTD) and/or maximum feasible dose (MFD).
provider
Gregory Aune, M.D. Pediatric Hematology Oncology , Adolescent & Young Adult Oncology
provider
Marcela Mazo Canola, MD Breast Oncology, Medical Oncology
provider
Sukeshi Patel Arora, MD Gastrointestinal Oncology, Geriatric Oncology
provider
Sherri Cervantez, MD Palliative Medicine, Thoracic Oncology
provider
Aaron Sugalski, DO Pediatric Oncology, Sarcoma Oncology
provider
Mary Salazar, ANP Adult Nurse Practitioner, Pancreatic - Hepatobiliary Oncology
provider
Kirsten Murray, MS, CGC Genetic Counseling, Cancer Genetics & High-Risk Screening
Clinical Trial
S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (CTMS# 23-0072)
The primary objective of the trial is to assess whether there is no difference in disease-free survival for patients treated with a 1cm excision margin when compared to a 2cm margin for stage II primary melanomas (AJCC 8th edition; pT2b-pT4b).